Mice with reduced NMDA receptor expression display behaviors related to schizophrenia

Cell

Volumn 98, Issue 4, 1999, Pages 427-436

  Mohn, Amy R ^a,b   Gainetdinov, Raul R ^c   Caron, Marc G ^c   Koller, Beverly H ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISOCIAL BEHAVIOR; ARTICLE; CLINICAL FEATURE; HYPERACTIVITY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DENSITY; SCHIZOPHRENIA; STEREOTYPY;

ANIMALIA;

EID: 0033588176     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81972-8     Document Type: Article

References (62)

1. Abi-Saab, W.M., D'Souza, D.C., Moghaddam, B., and Krystal, J.H. (1998). The NM DA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31 (Suppl 2), 104-109.
2. 3H]1-[1-(2-thienyl)cyclohexyl]piperidine binding to PCP site 2: further evidence that PCP site 2 is associated with biogenic amine reuptake complex. Neurochem. Res. 17, 261-264.
3. Anden, N.-E., Butcher, S.G., Corrodi, H., Fuxe, K., Ungerstedt, U. (1970). Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur. J. Pharmacol. 11, 303-314.
4. Angrist, B., Sathananthan, G., Wilk, S., and Gershon, S. (1974). Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatr. Res. 11, 13-23.
5. Ban, T.A., Guy, W., and Wilson, W.H. (1984). Description and distribution of the subtypes of chronic schizophrenia based on Leonhard's classification. Psychiatr. Dev. 2, 179-199.
6. Branbury Conference on Genetic Background in Mice (1997). Mutant mice and neuroscience: recommendations concerning genetic background. Neuron 20, 755-759.
7. Carlsson, M., and Carlsson, A. (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13, 272-276.
8. Carlsson, A., Hansson, L.O., Waters, N., and Carlsson, M.L. (1997). Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci. 61, 75-94.
9. Corbett, R., Hartman, H., Kerman, L.L., Woods, A.T., Strupczewski, J.T., Helsley, G.C., Conway, P.C., and Dünn, R.W. (1993). Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol. Biochem. Behav. 45, 9-17.
10. Corbett, R., Camacho, F., Woods, A.T., Kerman, L.L., Fishkin, R.J., Brooks, K., and Dunn, R.W. (1995). Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 120, 67-74.
11. Coyle, J.T. (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 3, 241-253.
12. Crawley, J.N., Belknap, J.K., Collins, A.., Crabbe, J.C., Frankel, W., Henderson, N., Hitzemann, R.J., Maxson, S.C., Miner, L.L., Silva, A.J., et al. (1997). Behavioral phenotypes of inbred mouse strains. Psychopharmacology 132, 107-124.
13. Das, S., Sasaki, Y.F., Rothe, T., Prekumar, Y.F., Takasu, M., Crandall, J.E., Dikkes, P., Conner, D.A., Rayudu, P.V., Cheung, W., et al. (1998). Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 393, 377-381.
14. Dixon, A.K., Huber, C., and Lowe, D.A. (1994). Clozapine promotes approach-oriented behavior in male mice. J. Clin. Psychiatry 55 Suppl B, 4-7.
15. Dombrowicz, D., Flamand, V., Brigman, K.K., Koller, B.H., and Kinet, J.P. (1993). Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobin E receptor alpha chain gene. Cell 75, 969-976.
16. Druhan, J.P., Rajabi, H., and Stewart, J. (1996). MK-801 increase locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens. Synapse 24, 135-146.
17. Ebralidze, A.K., Rossi, D.J., Tonegawa, S., and Slater, N.T. (1996). Modification of NMDA receptor channels and synaptic transmission bytargeted disruption of the NR2C gene. J. Neurosci. 16, 5014-5025.
18. Ellison, G. (1995). The N-methyl-D-aspartate antagonists phencyclidine, ketamine, dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Brain Res. Rev. 20, 250-267.
19. Ereshefsky, L., Watanabe, M.D., and Tran-Johnson, T.K. (1989). Clozapine: an atypical antipsychotic agent. Clin. Pharm. 8, 691-709.
20. Forrest, D., Yuzaki, M., Soares, H.D., Ng, L., Luk, D.C., Sheng, M., Stewart, C.L., Morgan, J.I., Connor, J.A., and Curran, T. (1994). Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 13, 325-338.
21. Franklin, K.B.J., and Paxinos, G. (1996). The Mouse Brain in Stereotaxic Coordinates (San Diego, CA: Academic Press).
22. Gainetdinov, R.R., Wetsel, W.C., Jones, S.R., Levin, E.D., Jaber, M., and Caron, M.G. (1999). Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283, 397-401.
23. Gerlach, J. (1991). New antipsychotics: classification, efficacy, and adverse effects. Schizophr. Bull. 17, 289-309.
24. Gingrich, J.A., and Caron, M.G. (1993). Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16, 299-321.
25. Giros, B., Jaber, M., Jones, S.R., Wightmann, R.M., and Caron, M.G. (1996). Hyperlocomotion and indifference to cocaine and amphet-amine in mice lacking the dopamine transporter. Nature 379, 606-612.
26. Gleason, S.D., and Shannon, H.E. (1997). Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129, 79-84.
27. Goff, D.C., and Wine, L. (1997). Glutamate in schizophrenia: clinical and research implications. Schizophr. Res. 27, 157-168.
28. Griffith, J.D., Cavanaugh, J., Held, J., and Oates, J.A. (1972). Dextroamphetamine: evaluation of psychotomimetic properties in man. Arch. Gen. Psychiatry 26, 97-100.
29. Hoffman, D.C., and Donovan, H. (1995). Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120, 128-133.
30. Hooper, M., Hardy, K., Handyside, A., Hunter, S., and Monk, M. (1987). HPRT-deficient (Lesen-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326, 292-295.
31. Hyttel, J. (1978). Dopamine-receptor binding and adenylate cyclase activity in mouse striatal tissue in the supersensitivity phase after neuroleptic treatment. Psychopharmacology (Berl) 59, 211-216.
32. Ikeda, K., Araki, K., Takayama, C., Inoue, Y., Yagi, T., Aizawa, S., and Mishina, M. (1995). Reduced spontaneous activity of mice defective in the epsilon 4 subunit of the NM DA receptor channel. Brain Res. Mol. Brain Res. 33, 61-71.
33. Imperato, A., Scrocco, M.G., Bacchi, S., and Angelucci, L. (1990). NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmacol. 187, 555-556.
34. Javitt, D.C., and Zukin, S.R. (1991 ). Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
35. Kelly, M.A., Rubinstein, M., Phillips, T.J., Lessov, C.N., Burkhar-Kasch, S., Zhang, G., Bunzow, J.R., Fang, Y., Gerhardt, G.A., Grandy, D.K., and Low, M.J. (1998). Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J. Neurosci. 18, 3470-3479.
36. Knable, M.B., Hyde, T.M., Herman, M.M., Carter, J.M., Bigelow, L., and Kleinmann, J.E. (1994). Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol. Psychiatry 36, 827-835.
37. Kutsuwada, T., Kashiwabuchi, N., Mori, H., Sakimura, K., Kushiya, E., Araki, K., Meguro, H., Masaki, H., Kumanishi, T., Arakawa, M., and Mishina, M. (1992). Molecular diversity of the NMDA receptor channel. Nature 358, 36-41.
38. Kutsuwada, T., Sakimura, K., Manabe, T., Takayama, C., Katakura, N., Kushiya, E., Natsume, R., Watanabe, M., Inoue, Y., Yagi, T., et al. (1996). Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice. Neuron 16, 333-344.
39. Lahti, R.A., Roberts, R.C., Conley, R.R., Cochrane, E.V., Mutin, A., and Tamminga, C.A. (1996). D2-type dopamine receptors in post-mortem human brain sections from normal and schizophrenic subjects. Neuroreport 7, 1945-1948.
40. Li, Y., Erzurumlu, R.S., Chen, C., Jhaveri, S., and Tonegawa, S. (1994). Whisker-related neuronal patterns fail to develop in the tri-geminal brainstem nuclei of NMDAR1 knockout mice. Cell 76, 427-437.
41. Luby, E.D., Cohen, B.D., Rosenbaum, F., Gottlieb, J., and Kelley, R. (1959). Study of a new schizophrenomimetic drug, Sernyl. Arch. Neural. Psychiatry 81, 363-369.
42. Malhotra, A.K., Pinals, D.A., Adler, C.M., Elman, I., Clifton, A., Pickar, D., and Breier, A. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17, 141-150.
43. A receptor antagonism is dependent on increased serotonergic tone. J. Neural Transm. 105, 365-396.
44. Masters, W.G., III., and Wheeler, M.B. (1996). Timing of induced ovulation in C. B-17/lcr-scid/scid and B6SJLF1 mice. Lab. Anim. Sci. 46, 663-666.
45. Meltzer, H.Y. (1991). The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17, 263-287.
46. Miller, D.W., and Abercrombie, E.D. (1996). Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res. Bull. 40, 57-62.
47. Moghaddam, B., and Adams, B.W. (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 287, 1349-1352.
48. Mohn, A.R., and Koller, B.H. (1995). Genetic manipulation of embryonic stem cells. In DNACloning 4: Mammalian Systems, D.M. Glover and B.D. Hames, eds. (New York, NY: Oxford University Press), pp. 141-184.
49. Monyer, H., Sprengel, R., Schoepfer, R., Her, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., and Seeburg, P.H. (1992). Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256, 1217-1221.
50. Nakanishi, S., Nakajima, Y., Masu, M., Ueda, Y., Nakahara, K., Watanabe, D., Yamaguchi, S., Kawabata, S., and Okada, M. (1998). Glutamate receptors: brain function and signal transduction. Brain Res. Brain Res. Rev. 26, 230-235.
51. Nankai, M., Klarica, M., Fage, D., and Carter, C. (1996). Evidence for native NMDA receptor subtype pharmacology as revealed by differential effects on the NMDA-evoked release of striatal neuromodulators. Neurochem. Int. 29, 529-542.
52. Nieollon, A., Krekerian, L., and Duticier, N. (1983). Presynaptic controls in the neostriatum: reciprocal interactions between the nigrostriatal dopaminergic neurons and the cortico-striatal glutamatergic pathway. Exp. Brain Res. (Suppl) 7, 54-65.
53. Nimgaonkar, V.L., Ward, S.E., Agarde, H., Weston, N., and Ganguli, R. (1997). Fertility in schizophrenia: results from a contemporary US cohort. Acta Psychiatr. Scand. 95, 364-369.
54. Odegard, O. (1980). Fertility of psychiatric first admissions in Norway 1936-1975. Acta Psychiatr. Scand. 62, 212-220.
55. Pierce, R.C., Meil, W.M, and Kalivas, P.W. (1997). The NM DA antagonist, dizocilpine, enhances cocaine reinforcement without influencing mesoaccumbens dopamine transmission. Psychopharmacology (Berl) 133, 188-195.
56. Rosenbauer, K.A., Campean, N., Campean, C., and Jansen, B. (1980). Studies concerning the formation of vaginal plug in laboratory animals and its suitability for demonstrating the ultrastructure of spermatazoa. Folia Morphol. (Praha) 28, 126-128.
57. Rothman, R.B. (1994). PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site. Neurotoxicol. Teratol. 16, 343-353.
58. Sakimura, K., Kutsuwada, T., Ito, I., Manabe, T., Takayama, C., Kushiya, E., Yagi, T., Aizawa, S., Inoue, Y., Sugiyama, H., et al. (1995). Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature 373, 151-155.
59. Saugstad, LF. (1989). Social class, marriage, and fertility in schizophrenia. Schizophr. Bull. 15, 9-43.
60. Seeman, P., Lee, T., Chau-Wong, and Wong, K. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
61. Tamminga, C.A. (1998). Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12, 21-36.
62. Wang, Y.-M., Gainetdinov, R.R., Fumagalli, F., Xu, F., Jones, S.R., Bock, C.B., Miller, G.W., Wightman, R.M., and Caron, M.G. (1997). Knockout of the vesicular monoamine transporter-2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285-1296.